India (National)
Not enough data
Indu Bhan's coverage is primarily focused on legal policy, regulation, government announcements with a strong emphasis on Supreme Court decisions and high-profile legal cases in India. She appears to be interested in issues related to tax deductions, arbitration, insolvency, debt recovery among others.
Given this focus, pitches should likely come from professionals knowledgeable about Indian law and court procedures. Individuals with expertise in tax laws or corporate litigation may want to consider reaching out when they have relevant insights into these topics. Additionally, those within the political and governmental sphere could also provide valuable commentary given Indu's interest in government announcements and policies.
Considering her national geographic focus (India), it would be beneficial for sources to tailor their pitches by highlighting relevance specifically within the Indian legal landscape.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Indu Bhan
The Supreme Court has directed the Centre and the Food Safety and Standards Authority of India to explain why a nationwide performance audit of food safety regulations is needed. This comes amid concerns over food adulteration and weak enforcement. The court seeks to understand the effectiveness of the current food safety framework.
By: Indu Bhan
The Supreme Court has asked the government and the Reserve Bank of India for their response to a petition that wants banks' dealings with real estate projects to be reviewed. The court also wants an investigation into developers accused of misusing homebuyers' money. Several authorities and builders have been issued notices.
By: Indu Bhan
In a landmark ruling, the Supreme Court has sided with Reliance Industries Ltd in a trading case that has spanned over 15 years. The court has annulled a substantial disgorgement order previously placed on the company, providing some relief. However, the Rs 25 crore fine levied by the Securities and Exchange Board of India (Sebi) stands firm.
By: Indu Bhan
The Supreme Court is examining an appeal by Lilavati Kirtilal Mehta Medical Trust, which had accused HDFC Bank MD Sashidhar Jagdishan of bribery. The Bombay High Court had previously quashed the case. The Supreme Court has asked for responses from the CBI and Mumbai Police. It noted that personal benefit allegations might still need scrutiny.
The court has annulled a substantial disgorgement order previously placed on the company, providing some relief.
By: Indu Bhan
The Delhi High Court's recent ruling has exonerated Samir K. Modi from defamation allegations made by independent directors Nirmala Bagri and Atul Kumar Gupta, who claimed their reputations were harmed. The court clarified that Modi's remarks were not aimed at them but were pertaining to his mother.
By: Indu Bhan
The Delhi High Court recently delivered a pivotal judgment, embracing the concept of the 'right to be forgotten', which is now embedded in Article 21 of the Constitution. This landmark ruling requires major search engines, like Google, along with legal databases, to eliminate searchable entries for certain court records tied to individuals.
By: Indu Bhan
The Delhi High Court division bench has ruled in favor of Intas Pharmaceuticals, allowing the company to introduce its anti-cancer medication, Bevatas, to the market. This decision overturns a previous block on the drug, affirming the court's view that Bevatas and Sun Pharma's Bevetex are sufficiently different in their ingredients and intended use.
GOQii Technologies has approached the Supreme Court. The fitness tech company wants a decision on customs duty for its imported bands. It argues they are pedometers, not communication devices. The Customs Tribunal classified them as communication devices. GOQii states Bluetooth is only for data syncing. The company claims the devices work independently.
By: Indu Bhan
The Delhi High Court has asked the Central Drugs Standard Control Organisation to review a petition challenging Zydus Lifesciences' approval for semaglutide injections. A diabetes patient raised concerns about the drug's delivery system, alleging it deviates from global standards and poses health risks. The court has directed the CDSCO to consider the patient's representation within two months.
